On 2/14/2012 Karo Bio (Stockholm $KARO; OTC $KARBF.PK) announced the termination of their eprotirome program for dyslipidemia after discovering long-term safety issues in preclinical studies.
This eliminates a competitor for ISIS (KYNAMRO aka mipomersen) and AEGR.
The company had planned to spin off their preclinical research and development operations, but since that is all they have now, those plans have been scrapped. Does anyone have any comment about these programs? See embedded slide deck below if interested.
This eliminates a competitor for ISIS (KYNAMRO aka mipomersen) and AEGR.
The company had planned to spin off their preclinical research and development operations, but since that is all they have now, those plans have been scrapped. Does anyone have any comment about these programs? See embedded slide deck below if interested.
This is your new blog post. Click here and start typing, or drag in elements from the top bar.
RSS Feed
